EGFR and non-small cell lung carcinoma: The hsa-miR-133b [66] significantly inhibits cell proliferation in non-small cell lung cancer (NSCLC) by directly targeting the epidermal growth factor receptor (EGFR) and disrupting its downstream signaling pathways.